Skip to Main content Skip to Navigation
Journal articles

Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort

Guillaume Fond 1 Laurent Boyer 2 Fabrice Berna 3 Ophélia Godin 4 Ewa Bulzacka 5 Meja Andrianarisoa 5 Lore Brunel 5 Bruno Aouizerate 6 Delphine Capdevielle 7 Isabelle Chéreau 8 Nathalie Coulon 5 Thierry d'Amato 9 Caroline Dubertret 5 Julien Dubreucq 10 Catherine Faget 11 Sylvain Leignier 10 Christophe Lançon 12 Jasmina Mallet 5 David Misdrahi 5 Christine Passerieux 13 Romain Rey 5 Aurélie Schandrin 1 Mathieu Urbach 5 Pierre Vidailhet 5 Marion Leboyer 14 Franck Schürhoff 15 Pierre-Michel Llorca 16
Abstract : Background Major depressive disorder (MDD) is underdiagnosed and undertreated in schizophrenia, and has been strongly associated with impaired quality of life. Aims To determine the prevalence and associated factors of MDD and unremitted MDD in schizophrenia, to compare treated and non-treated MDD. Method Participants were included in the FondaMental Expert Centers for Schizophrenia and received a thorough clinical assessment. MDD was defined by a Calgary score ≥6. Non-remitted MDD was defined by current antidepressant treatment (unchanged for >8 weeks) and current Calgary score ≥6. Results 613 patients were included and 175 (28.5%) were identified with current MDD. MDD has been significantly associated with respectively paranoid delusion (odds ratio 1.8; P = 0.01), avolition (odds ratio 1.8; P = 0.02), blunted affect (odds ratio 1.7; P = 0.04) and benzodiazepine consumption (odds ratio 1.8; P = 0.02). Antidepressants were associated with lower depressive symptoms score (5.4 v. 9.5; P < 0.0001); however, 44.1% of treated patients remained in non-remittance MDD. Nonremitters were found to have more paranoid delusion (odds ratio 2.3; P = 0.009) and more current alcohol misuse disorder (odds ratio 4.8; P = 0.04). No antidepressant class or specific antipsychotic were associated with higher or lower response to antidepressant treatment. MDD was associated with Metabolic syndrome (31.4 v. 20.2%; P = 0.006) but not with increased C-reactive protein. Conclusions Antidepressant administration is associated with lower depressive symptom level in patients with schizophrenia and MDD. Paranoid delusions and alcohol misuse disorder should be specifically explored and treated in cases of non-remission under treatment. MetS may play a role in MDD onset and/or maintenance in patients with schizophrenia. Declaration of interest None.
Complete list of metadatas

https://hal.uca.fr/hal-01814845
Contributor : Marie-Laurence Douhairie <>
Submitted on : Wednesday, June 13, 2018 - 3:43:18 PM
Last modification on : Wednesday, July 15, 2020 - 8:58:04 AM

Links full text

Identifiers

Citation

Guillaume Fond, Laurent Boyer, Fabrice Berna, Ophélia Godin, Ewa Bulzacka, et al.. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. British Journal of Psychiatry, Royal College of Psychiatrists, 2018, 213 (2), pp.464-470. ⟨10.1192/bjp.2018.87⟩. ⟨hal-01814845⟩

Share

Metrics

Record views

583